Leo Pharma overhauls structure, management; U.S. patent board takes up another patent on long-acting Copaxone;

@FiercePharma: India's Maharashtra state asks blood banks to send plasma to Reliance Life Sciences in albumin shortage. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says. Report | Follow @CarlyHFierce

> The Danish specialty drugmaker Leo Pharma is revamping its top management and restructuring operations, setting up three regional divisions while integrating global R&D and administrative functions. Release

> The U.S. Patent and Trademark Office will review a third patent on Teva Pharmaceutical's ($TEVA) long-acting dose of the multiple sclerosis drug Copaxone, according to generics maker Mylan ($MYL), which filed an inter partes challenge at the U.S. agency. Release

> The FDA expanded approval for Merck & Co.'s ($MRK) chemotherapy-related nausea drug Emend for use in some children. Release

> Tesaro ($TSRO) won FDA approval for its first drug, Varubi, a treatment for chemo-related nausea and vomiting in adults. Release

> Allergan ($AGN) said the official FDA labeling on its anti-infective drug Teflaro was updated to support a shorter infusion time. Release

> European regulators gave the green light to Novartis' ($NVS) first-in-class drug Revolade for patients with severe aplastic anemia. Release

Medical Device News

@FierceMedDev: Agena Bioscience opening office in China, aims to sell spectrometry systems in the country. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Quanterix and Banyan Biomarkers forge ahead with brain injury diagnostic tech. More | Follow @VarunSaxena2

@EmilyWFierce: DynoSense selects Chinese marketing partner for handheld monitoring device. Story | Follow @EmilyWFierce

> HeartWare looks to diversify into mitral valve repair with $929M purchase of Valtech Cardio. Story

> FDA partners with nonprofit device incubator Fogarty Institute to improve approval efficiency. More

Biotech News

@FierceBiotech: ICYMI yesterday: Gene therapy upstart Audentes bags a new program in buyout. Article | Follow @FierceBiotech

@JohnCFierce: From the early hours file: AstraZeneca backs $80M round for ADC's antibody warhead tech. News | Follow @JohnCFierce

@DamianFierce: ICYMI yesterday: AstraZeneca auctions off troubled psoriasis drug to Valeant in $445M deal. More | Follow @DamianFierce

> Amgen's bone drug beats Lilly's Forteo in a Phase III osteoporosis trial. Report

> In neuroscience swap, Amgen buys into Novartis' BACE drug program for Alzheimer's. More

> Sanofi punts a $200M Ardelyx deal and hands back some preclinical drugs. Article

Biotech Research News

> TGen IDs targets for nonalcoholic fatty liver disease. Item

> Ziopharm tests new approach to engineering CAR-Ts for solid tumors. Report

> Eta-amyloid discovered in Alzheimer's adds new piece to the complex puzzle. More

> New research highlights role of SKA2 gene in PTSD, suicide. Article

> Gene variant linked to a 10-year delay in Alzheimer's onset. Story

Diagnostics News

> FDA scolds Cepheid for manufacturing issues in Sweden. More

> Exact Sciences wins CMS panel vote for Cologuard pricing. Report

> JAMA: Two genetic tests, not one, could work better at diagnosing autism. More

> Agena Bioscience opening office in China, aims to sell spectrometry systems in the country. Story

> FDA scolds Cepheid for manufacturing issues in Sweden. Article

Pharma Marketing News

> Bristol-Myers' Opdivo snags FDA priority review for bigger lung cancer use. Item

> Pharma TV ads are good for the business bottom line, study says. Report

> New Pradaxa antidote study preps Boehringer for market-share turnaround: ESC. Story

> AstraZeneca sales team revving up for new Brilinta marketing push. More

> Valeant bets the odds on AZ's psoriasis med in $100M-plus development deal. Article

And Finally... The FDA warned 5 companies that sell powdered caffeine, saying the products are potentially dangerous. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.